Pharmaceuticals
Kamada Intensifies Efforts to Highlight CYTOGAM's Role in CMV Management for Transplant Patients
Kamada Ltd. is amplifying its commitment to organ transplant patients by enhancing awareness and research around CYTOGAM, its treatment for cytomegalovirus (CMV), a potentially deadly complication for transplant recipients.
Nutriband Inc. Advances Abuse-Deterrent Buprenorphine Therapy with AVERSA Technology
Nutriband Inc. is pioneering a novel transdermal delivery system for buprenorphine, aiming to address the opioid epidemic with safer treatment options, potentially revolutionizing pain and addiction therapies.
Scinai Immunotherapeutics Clears Italian Regulatory Hurdle for Pincell Acquisition
Scinai Immunotherapeutics Ltd. has received Italian regulatory approval to proceed with its option to acquire Pincell S.r.l., a move that could significantly expand its inflammation and immunology pipeline with Pincell's promising monoclonal antibody, PC111.
CNS Pharmaceuticals Inc. to Showcase Glioblastoma Treatment Advancements at Brain Tumor Biotech Summit
CNS Pharmaceuticals Inc. will present promising data on its brain-penetrating taxane candidate, TPI 287, at the upcoming Brain Tumor Biotech Summit, highlighting potential breakthroughs in treating glioblastoma and other CNS tumors.
Telomir Pharmaceuticals Reports Preclinical Breakthrough in Age-Reversal with Telomir-1
Telomir Pharmaceuticals' preclinical results for Telomir-1 show promising age-reversal effects in a zebrafish model of Werner Syndrome, highlighting potential advancements in longevity science.
Tonix Pharmaceuticals to Showcase Rheumatologic Research at EULAR 2025
Tonix Pharmaceuticals Holding Corp. is set to present its latest research at the Annual European Congress of Rheumatology (EULAR) 2025, highlighting advancements in rheumatologic conditions and its broader pipeline.
Nutriband Inc. to Showcase Innovations at Noble Capital Markets Emerging Growth Virtual Conference
Nutriband Inc. (NASDAQ: NTRB) is set to present at the Noble Capital Markets Emerging Growth Virtual Equity Conference, highlighting its advancements in abuse-deterrent transdermal pharmaceutical products, a critical step in addressing the opioid crisis.
Repertoire Immune Medicines Strengthens Leadership with Appointment of Dr. Robert Andtbacka as Chief Medical Officer
Repertoire Immune Medicines appoints Dr. Robert Andtbacka as Chief Medical Officer, marking a significant step in advancing its pipeline of T cell-targeted therapies for cancer and autoimmune diseases.
Nutriband Inc.'s AVERSA Technology Poised for FDA Approval with Significant Market Potential
Nutriband Inc.'s innovative AVERSA abuse-deterrent patch technology, targeting the misuse of transdermal patches like fentanyl, is on its way to FDA approval, with an estimated annual market potential of $800 million.
Pfizer Faces Lawsuit Over Contraceptive Injection Linked to Brain Tumors
Hundreds of women from the U.S. and U.K. are suing Pfizer after a study linked its contraceptive injection to a significantly increased risk of brain tumors, highlighting potential health risks associated with pharmaceutical products.
NanoViricides Advances Measles Drug Program as Global Outbreaks Rise
NanoViricides, Inc. has begun animal trials for its antiviral candidate NV-387, targeting measles amidst increasing global outbreaks and vaccine challenges, highlighting a critical step towards addressing a significant public health gap.
CareMetx Strengthens Leadership Team with Appointment of Brian Flaherty as Chief Commercial Officer
CareMetx enhances its leadership by appointing Brian Flaherty as Chief Commercial Officer, aiming to improve patient access to specialty therapies through strategic commercial initiatives.
Jean Witz Joins Wilson Sonsini as Senior Patent Counsel, Bolstering Firm's Expertise in Biotechnology and Pharmaceuticals
Jean Witz, with nearly 40 years of experience in patent law and a distinguished career at the USPTO, joins Wilson Sonsini as senior patent counsel, enhancing the firm's capabilities in biotechnology, pharmaceuticals, and chemical engineering.
Catalio Capital Invests in $130 Million Series B Funding for GlycoEra to Advance Autoimmune Disease Treatments
Catalio Capital Management has participated in a $130 million Series B funding round for GlycoEra AG, a Swiss biotech firm, to develop innovative treatments for autoimmune diseases, marking a significant step forward in life sciences investment and healthcare innovation.
Telomir Pharmaceuticals Advances Telomere-Targeting Drug, Seeks Strategic Partnerships
Telomir Pharmaceuticals is preparing to submit an Investigational New Drug (IND) application for Telomir-1, a potential breakthrough small molecule targeting aging mechanisms, with plans to explore strategic collaborations at the BIO International Convention 2025.
Nutriband Reports Record Q1 Revenue, Advances Abuse-Deterrent Fentanyl Patch Development
Nutriband Inc. reported a 63% year-over-year revenue increase in Q1, driven by expanded kinesiology tape production and retail presence, while simultaneously progressing its AVERSA Fentanyl patch development through a strategic partnership with Kindeva Drug Delivery.
NanoViricides Reveals Breakthrough Antiviral Platform at BIO International Convention
NanoViricides will showcase its novel NV-387 broad-spectrum antiviral drug candidate, which demonstrates promising preclinical efficacy against multiple viral infections, potentially revolutionizing viral treatment approaches.
Quantum BioPharma Advances Clinical Trial for MCAS Pain Treatment
Quantum BioPharma has received Australian ethics approval for a Phase 2 clinical trial of FSD202, a potential treatment for chronic pain associated with Mast Cell Activation Syndrome (MCAS), signaling progress in addressing a challenging medical condition.
Nutriband Seeks to Revolutionize Transdermal Pain Management Through Innovative Abuse-Deterrent Technology
Nutriband is developing a groundbreaking transdermal drug delivery platform aimed at addressing pain management challenges in the wake of the opioid crisis, focusing on creating safer, more accessible opioid therapies.
Soligenix Develops Novel Therapy to Address Antibiotic-Resistant Bacterial Infections
Soligenix's SGX943 represents a potential breakthrough in combating antibiotic-resistant bacteria, offering a novel broad-spectrum therapy that could help address a critical public health challenge.
Nutriband Advances Opioid Patch Technology with Potential Abuse-Deterrent Solution
Nutriband is making significant progress toward commercializing its AVERSA Fentanyl technology, partnering with Kindeva Drug Delivery to develop a potentially groundbreaking opioid pain patch with abuse-deterrent properties.
Soligenix's HyBryte Shows Promising Results in Rare Cancer Treatment
Soligenix reports significant progress in treating cutaneous T-cell lymphoma (CTCL) with its experimental therapy HyBryte, demonstrating 75% treatment success after 18 weeks of clinical trials. The breakthrough offers potential hope for patients with this challenging rare skin cancer.
NanoViricides Highlights Potential Antiviral Solution Amid Changing COVID Booster Recommendations
NanoViricides' President Dr. Anil Diwan comments on the FDA's updated COVID-19 booster policy, emphasizing the need for alternative antiviral treatments and positioning the company's NV-387 drug candidate as a potential solution for respiratory viral infections.
Tonix Pharmaceuticals CEO Highlights Strategic Developments at A.G.P. Healthcare Showcase
Tonix Pharmaceuticals CEO Seth Lederman shared key strategic insights during a fireside chat, emphasizing the company's integrated business model and advanced clinical pipeline, with particular focus on potential treatments for fibromyalgia and potential defense-related medical innovations.
Telomir Pharmaceuticals Secures $3M Investment to Advance Age-Reversal Research
Telomir Pharmaceuticals has received a strategic $3 million equity investment from The Bayshore Trust, bolstering its efforts to develop potential breakthrough therapies targeting age-related diseases and longevity.
Aditxt Terminates Acquisition Agreement with Appili Therapeutics
Aditxt Inc. has decided to end its planned acquisition of Appili Therapeutics, citing a lack of strategic alignment. The termination highlights potential challenges in healthcare innovation partnerships.
CNS Pharmaceuticals Advances Brain Cancer Treatment, Reports Q1 Financial Results
CNS Pharmaceuticals is progressing its brain cancer treatment TPI 287, with increased R&D spending and plans for a Phase 2 study in recurrent glioblastoma multiforme, while maintaining financial runway into 2026.
NanoViricides Advances Broad-Spectrum Antiviral Drug, Eyes Multiple Phase II Trials
NanoViricides is progressing its NV-387 drug candidate across multiple viral infections, with pending Phase II trials for MPox and emerging programs for measles and avian flu, highlighting significant potential in antiviral treatment development.
Nutriband Expands Pharma Footprint with Strategic Partnerships
Nutriband Inc. strengthens its market position through strategic alliances with Charlotte FC and Kindeva Drug Delivery, focusing on its innovative abuse-deterrent transdermal drug delivery technology.
Telomir Pharmaceuticals Reveals Innovative Silver(II) Antimicrobial Drug Candidate
Telomir Pharmaceuticals has developed Telomir-Ag2, a novel Silver(II) complex with broad-spectrum antimicrobial properties targeting significant medical markets including wound care and infection treatment.